Comparison

VEGFR-3 (FLT4) Antibody (N-term) Blocking peptide

Item no. ABC-BP7645a
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Lyophilized
Specific against other
Citations Walter, J.W., et al., Genes Chromosomes Cancer 33(3):295-303 (2002).Karkkainen, M.J., et al., Nat. Genet. 25(2):153-159 (2000).Irrthum, A., et al., Am. J. Hum. Genet. 67(2):295-301 (2000).Ferrell, R.E., et al., Hum. Mol. Genet. 7(13):2073-2078 (1998).Galland, F., et al., Oncogene 8(5):1233-1240 (1993).
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias Vascular endothelial growth factor receptor 3,VEGFR-3,Fms-like tyrosine kinase 4,FLT-4,Tyrosine-protein kinase receptor FLT4,FLT4,VEGFR3
Similar products VEGFR-3, FLT4, VEGFR3, Vascular endothelial growth factor receptor 3, Fms-like tyrosine kinase 4, Tyrosine-protein kinase receptor FLT4, FLT-4
Available
Manufacturer - Category
Peptides; Blocking Peptides
Manufacturer - Targets
The synthetic peptide sequence used to generate the antibody AP7645a was selected from the N-term region of human FLT4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Bio Background
VGFR3, a member of the CSF-1/PDGF receptor subfamily of Tyr protein kinases, is a receptor for VEGFC. This Type I membrane protein is expressed in placenta, lung, heart, and kidney, but does not seem to be expressed in pancreas and brain. Defects in FLT4 are the cause of hereditary lymphedema I, also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment. Hereditary lymphedema I shows autosomal dominant inheritance and is characterized by onset usually at birth. Defects in FLT4 are also found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10/% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
Gene Name
FLT4
Subtitle
Synthetic peptide
Formulation
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close